Industry:
Active Pharmaceutical Ingredients
Location:
Suzhou, Cina
Investment Date:
December 2010
Status:
Disinvested (June 2015)
Type of investment:
Replacement Capital

Tianma Tianji

Tianma Tianji produces Active Pharmaceutical Ingredients (APIs) for generic medicines, formulations (lyophilized and small volume injection dosages) and peptide products. At the time of MCP’s investment, the company was China’s largest supplier of APIs for reference formulations and employed about 500 people at its plant in Suzhou, Shandong.

Website:
www.tianjibio.com